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b Department of Experimental Medicine, University of Rome Tor Vergata, Via Montpellier, 1, 00133 Rome, ItalyIn 1998, Steinmuller et al. described a previously unrecognized syn- hemizygous missense variant c.1294C N T in EIF2S3 (p.Pro432Ser) in
drome featuring mental retardation, epileptic seizures, hypogonadism,
microcephaly, and obesity (MEHMO syndrome; MIM 300148) and
mapped the disease locus to Xp22.13-p21 [7]. Interestingly, in addition
to the symptoms/signs included in the acronym MEHMO, the proband
presentedwith non-autoimmune diabetes at the age of 6months, a con-
dition currently defined as neonatal diabetes [1]. Diabetes was not re-
ported in the other three affected males of the family who died at 7, 2
and 10 months of age. Fourteen years later, Borck [2] identified a hemi-
zygous missense mutation (p.Ile223Thr) in the eukaryotic translation
initiation factor 2 subunit 3 (EIF2S3, or eIF2γ) in threemales froma con-
sanguineous family of Moroccan Jewish ancestry that disrupted EIF2
complex formation, resulting in defects in translation initiation, and
MEHMO phenotype (Borck however did not associate the mutation
with MEHMO syndrome.). Since then, EIF2S3mutations have been de-
scribed including the Ile465Ser*fs 4 found in the original family re-
ported by Steinmuller, and in two additional individuals with MEHMO
and early-onset (b1 year of age), non-autoimmune diabetes [6]. Other
two missense mutations, p.Ser108Arg and p.Ile259Met were detected
in three patients all exhibiting the main features of MEHMO's pheno-
type, and other endocrine manifestations such as growth hormone de-
ficiency (GHD) and hypoglycaemia [4].
A study published in the current issue of EBioMedicine has expanded
the spectrum of EIF2S3 variants. It describesmonozygotic twin brothers
and their maternal cousin, born to a non-consanguineous white
European pedigree, that presented with normal head circumferences,
mild learning difficulties, severe recurrent hypoglycaemia, short stature
with GHD, and thyrotropin (TSH) deficiency. There was also an unusual
metabolic phenotype fluctuating between post-prandial
hyperglycaemia and hyperinsulinaemic hypoglycaemia that remitted
before puberty with persistence of glucose dysregulation characterized
by post-prandial hyperglycaemia and variable, fasting hypoglycaemia
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in heterozygous state.
To get a better insight of the effects determined by EIF2S3/Pro432Ser
at the level of hypothalamic-pituitary and endocrine pancreas cells, sev-
eral functional analyses were performed, including in situ hybridization
on human embryonic tissues, EIF2S3-knockdown studies in the human
hybrid pancreatic cell line 1.1B4 (coupled with an apoptosis assay), and
the effect of humanized mutated protein on translational control in
yeast.
In situ hybridization revealed that EIF2S3 mRNA is strongly
expressed in the pancreatic islet of 13 week-old human foetus, suggest-
ing a role of eIF2γ in the developing endocrine pancreas. In addition,
EIF2S3 signal was detected in the hypothalamus, Rathke's pouch, ante-
rior and posterior pituitary, and progenitor cells of the nasal epithelium
and retina. 1.1B4 cell clones with reduced (82% reduction) EIF2S3 gene
expression, obtained by gene knockdown, was associated with en-
hanced caspase activity, suggesting that the decreased viability ob-
served in these 1.1B4 cell clones is likely linked to apoptosis.
With an elegant experimentAuthors show that yeast Pro490Sermu-
tation (corresponding to human eIF2γ/Pro432Ser) leads to a slight but
measurable increase of GCN4 gene expression, with modestly impaired
translational control and start codon selection stringency. In contrast,
yeast mutation Ile318Met (corresponding to human mutation eIF2γ/
Ile259Met, associated with “classic” MEHMO phenotype) [4] showed
an extremely reduced eIF2γ function.
Overall, this data indicates that the EIF2S3/Pro432Ser mutation im-
pacts moderately on eIF2γ functionality, and this may justify the depar-
ture from standard MEHMOs. features. In addition, the peculiar
metabolic phenotype found in these three patients indicates that
hypoglycaemia and non-autoimmune diabetes are frequent in
MEHMO syndrome [8], maybe calling for a revision of the acronym.
In this report the authors demonstrate whole-exome sequencing as
a successful approach to identify novel candidate genes underlying
syndromic hypopituitarism associated with combined pituitary defects
and pancreatic dysfunction. The insights provided by this study suggest
that the Pro432Ser variant would cause a relatively mild phenotype of
MEHMO syndrome compared to what was previously reported in the
literature and have a role in the developing endocrine organs. Brain
MRI in the three boys provided evidence of a small anterior pituitary
with a normal posterior pituitary and stalk which is associated withthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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pituitary development and function. It also suggests an additional, im-
portant role of EIF2S3 in the organization of central hormone secretion.
Moreover, the high EIF2S3 expression found in the developing endo-
crine pancreas, and the early presentation of hypoglycaemia and diabe-
tes in most of MEHMO syndrome's patients suggests that eIF2γ may
play a crucial role in glucose metabolism, like EIF2AK3 in Wolcott-
Rallison syndrome. Of note, EIF2S3 is included in the panel of genes
studied in patients with syndromic neonatal diabetes (https://www.
diabetesgenes.org/tests-for-diabetes-subtypes/targeted-next-
generation-sequencing-analysis-of-45-monogenic-diabetes-genes/). At
this point in time however, the pathophysiology of hypoglycaemia in
these patients is not clear. While hyperinsulinaemic hypoglycaemia
can be observed in patients carrying HNF4A or ABCC8 mutations who
develop diabetes later in life [5,9], hyper- and hypoglycaemia coexist
in individuals described in Gregory's paper in a way that resembles pa-
tients with mutations in the insulin receptor gene [10]. Further studies
are needed to clarify this issue, including the impact of EIF2S3mutations
on pancreatic α cell function and glucagon secretion.
MEHMO syndrome should be suspected early in male patients with
a milder phenotype of learning difficulties, growth delay and hormonal
deficiencies as well as glucose dysregulation. Timely diagnosis and
treatment of hormone defects and hypoglycaemia may be critical for
the prevention of significant neurodevelopmental delay.
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